Quantcast
Last updated on April 16, 2014 at 13:56 EDT

Latest Proteasome Stories

2014-01-16 16:23:55

Five Distinguished Researchers Receive First-Time Grant WHITE PLAINS, N.Y., Jan. 16, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today is pleased to announce the researchers who will receive funding through The Screen to Lead program - a new grant program to support drug discovery specifically directed toward medicinal chemistry and/or drug target screening in blood cancers. LLS recognizes investigators' significant need for resources to develop small molecules...

2013-11-22 23:20:45

Histone Methyltransferases: Global Markets for Research Tools, Diagnostics and Drug Discovery, increased R&D spending in the development of epigenetic tools and assays for Histone Methyltransferases (HMT) research, HMTs use as biomarkers and targets for diagnostics development and the drug discovery sector will drive tremendous growth in this market for the foreseeable future. BCC Research projects the market to grow to $275 million by 2018, and register a five-year compound annual...

2013-10-07 23:20:22

Reportbuyer.com just published a new market research report: Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery. London (PRWEB) October 07, 2013 STUDY GOALS AND OBJECTIVES This BCC Research report, Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery, provides an overview of the current overall state of ubiquitin proteasome market, focusing specifically on research tools, assay development, drug candidates and...

2013-07-23 23:19:33

According to a new technical market research report, the global ubiquitin proteasome research and development market was valued at nearly $2.9 billion in 2013. BCC Research expects the market to reach more than $5.5 billion by 2018, and register a five-year compound annual growth rate (CAGR) of 14.2% for the period 2013 to 2018. Wellesley, MA (PRWEB) July 23, 2013 According to a new technical market research report, Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and...

2013-07-18 11:43:53

Precise action sets agents apart from existing anti-cancer therapies Molecular biologists in the School of Medicine at The University of Texas Health Science Center San Antonio have found a novel way to fine-tune the activity of cells' protein-disposing machinery, with potentially cancer-fighting effects. This machinery, the proteasome, is deregulated in cancer. Agents called protease inhibitors are viewed as potential anti-cancer therapies, but they indiscriminately curb proteasome...

2013-05-28 21:38:10

Cells have a sophisticated system to control and dispose of defective, superfluous proteins and thus to prevent damage to the body. Dr. Katrin Bagola and Professor Thomas Sommer of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch as well as Professor Michael Glickman and Professor Aaron Ciechanover of Technion, the Technical University of Israel in Haifa, have now discovered a new function of an enzyme that is involved in this vital process. Using yeast cells as...

2013-04-30 13:46:56

Scientists have devised a method for delivering tumor cell-killing enzymes in a way that protects the enzyme until it can do its work inside the cell. In their study in mBio®, the online open-access journal of the American Society for Microbiology, researchers assembled microscopic protein packages that can deliver an enzyme called PEIII to the insides of cells. By attaching a protein called ubiquitin to the enzyme, they were able to protect it from degradation by the cell, allowing the...

2013-04-26 14:11:20

Proteins, unlike diamonds, aren't forever. And when they wear out, they need to be degraded in the cell back into amino acids, where they will be recycled into new proteins. Researchers at Rockefeller University and the Howard Hughes Medical Institute have identified a new way that the cell's protein recycler, the proteasome, takes care of unwanted and potentially toxic proteins, a finding that has implications for treating muscle wasting, neurodegeneration and cancer. The consensus among...

2013-04-09 08:29:31

SAN FRANCISCO, April 9, 2013 /PRNewswire/ -- Cleave Biosciences announced today it has raised $10 million in an extension of its Series A financing from new investor New Enterprise Associates (NEA), bringing its Series A total to $54 million. In the fall of 2011, Cleave raised $44 million from US Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors, Astellas Venture Management and Osage University Partners to fund the biopharmaceutical company's cancer drug discovery...

2013-01-15 10:44:38

Using an innovative approach, scientists at The Scripps Research Institute (TSRI) have determined the structure of Ltn1, a recently discovered “quality-control” protein that is found in the cells of all plants, fungi and animals. Ltn1 appears to be essential for keeping cells´ protein-making machinery working smoothly. It may also be relevant to human neurodegenerative diseases, for an Ltn1 mutation in mice leads to a motor-neuron disease resembling amyotrophic lateral...